Developing small molecule kinase inhibitors

We specialize in formulation development of injectable peptides and proteins tailored for first human use.

Discovery and development of novel antibiotics to treat multidrug-resistant infections. 

Specialized in fusion molecules based on secondary metabolites from eukaryotes.

formerly known as Arxx Therapeutics, develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis